IP Library Granted Patent US 7,402,406
Granted Patent B2
US 7,402,406 · App. 10/493,057 · Granted Jul 22, 2008

Methods of evaluating phosphatase inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,402,406
App. No.
10/493,057
Granted
Jul 22, 2008
Kind
B2
Abstract

The present invention identified OVARC1000473 (SEQ ID NO: 1) and NT2RM1000377 (SEQ ID NO: 3) as clones showing suppression of CREB activation by forskolin, and provides evaluation methods using these genes, and/or proteins encoded by these genes. Furthermore, these proteins were found to enhance cell damage. Compounds that can be screened based on the evaluation methods of this invention are useful as agents for inhibiting the CREB dephosphorylation reaction, agents for suppressing enhancement of cell damage, and preventive and therapeutic agents for memory disorders and/or neurodegenerative disorders.

Claims (16)

1. A method for detecting a compound which inhibits dephosphorylation of a cAMP responsive element binding protein (CREB), wherein the method comprises

contacting a protein with (A) CREB and a protein kinase that phosphorylates CREB to phosphorylate CREB, or (B) a phosphorylated CREB in the presence or absence of a test compound, measuring the phosphorylation level of CREB;

wherein a higher level of phosphorylation in the presence of the test compound compared to the absence of the compound is indicative that the compound inhibits dephosphorylation of CREB, and:

wherein (1) the protein comprises the amino acid sequence of SEQ ID NO: 4, (2) the protein is encoded by a polynucleotide that hybridizes under stringent conditions with the full length complement of SEQ ID NO: 3, wherein the stringent conditions comprise a washing step in 0.1×SCC and 0.1% SDS at 65° C., and wherein the protein has CREB dephosphorylation activity; or (3) the protein comprises an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 4, wherein the protein has CREB dephosphorylation activity.

2. The method of claim 1 , wherein the CREB phosphorylation level is measured, using as an index, the transcriptional activity of a CREB-regulated gene.

3. The method of claim 1 , wherein the protein comprises the amino acid sequence of SEQ ID NO:4.

4. The method of claim 1 , wherein, the protein is encoded by a polynucleotide that hybridizes under stringent conditions with the full length complement of SEQ ID NO: 3, wherein the stringent conditions comprise a washing step in 0.1×SCC and 0.1% SDS at 65° C. and wherein the protein has CREB dephosphorylation activity.

5. The method of claim 1 , wherein the protein comprises an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 4, wherein the protein has CREB dephosphorylation activity.

6. The method of claim 1 , wherein the method comprises contacting the protein in the presence of CREB and a kinase to phosphorylate CREB in the presence or absence of the test compond.

7. The method of claim 6 , wherein the CREB phosphorylated site is a serine at position 133 of CREB.

8. The method of claim 1 , wherein the method comprises contacting a test compound with a protein in the presence of a phosphorylated CREB.

9. The method of claim 1 , wherein the CREB phosphorylated site is a serine at position 133 of CREB.

10. The method of claim 1 , wherein the contacting occurs in a cell.

11. The method of claim 10 , wherein the cell comprises a polynucleotide encoding CREB.

12. The method of claim 10 , wherein the cell comprises a polynucleotide encoding the protein.

13. The method of claim 11 , wherein the cell comprises a polynucleotide encoding the protein.

Assignments (2)
MERGER Recorded Dec 12, 2005
From: FUJISAWA PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 017073/0257 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2004
From: MORITA, MASAHIKO; ARAKAWA, HIROYUKI; YAMAZAKI, MAYAKO; SATOH, SUSUMU; NISHIMURA, SHINTARO; KITA, YASUHIRO; YAMAZAKI, TAKAO
To: FUJISAWA PHARMACEUTICAL CO., LTD.
Reel/Frame 015579/0598 →